Detection kit of serum transporter marker ITG beta3 and application of detection kit as breast cancer brain metastasis molecular marker
By designing a serum migratory marker ITGβ3 detection kit for detecting brain metastasis in breast cancer, and combining dPCR technology, the problem of early diagnosis of brain metastasis in breast cancer is solved, and ITGβ3 detection with high sensitivity and accuracy is achieved, which significantly improves BCBM Patient diagnosis and prognosis evaluation.
Patent Information
- Application Number
- CN202411404684.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively detect the serum migratory marker ITGβ3 in breast cancer brain metastasis (BCBM), which leads to early diagnosis and affects patient prognosis.
A detection kit for the serum migrator marker ITGβ3 was designed, combined with digital PCR (dPCR) technology, and the ITGβ3 mRNA in serum migratory was detected through upstream and downstream primers to achieve absolute quantitative analysis of high sensitivity, specificity and accuracy. .
It can predict the existence of BCBM early, provide accurate diagnostic information, and provide reference for the prognosis evaluation of breast cancer, significantly improving the diagnostic accuracy and basis for treatment decisions in BCBM patients.
Smart Images

Figure CN118910266A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of gene detection, and in particular relates to a detection kit for serum migratoria marker ITGβ3 and its application as a molecular marker for brain metastasis of breast cancer. Background Art
[0002] Breast cancer is the most common malignant tumor in women worldwide, and distant metastasis is the most serious complication of breast cancer in the late stage. The brain is one of the most common sites of metastasis, and approximately 10-15% of breast cancer patients will develop brain metastases. Breast cancer brain metastases (BCBM) seriously affect patients' cognitive and sensory functions, resulting in severe limitations in their quality of life. BCBM has a high mortality rate and extremely poor prognosis, with a median survival of only 6 months and a 1-year survival rate of less than 20%. Since brain metastases in breast cancer patients often exist in a single form, when metastases form isolated lesions with the dura mater as the base, traditional imaging examinations are often unable to confirm the diagnosis. Therefore, seeking an early diagnostic biomarker for BCBM has become a key issue that needs to be solved urgently. This not only helps to achieve early diagnosis of the disease, but also promotes the development of targeted drugs, which has important guiding significance for clinical practice.
[0003] Migrasomes are a newly discovered new type of organelle that depends on cell migration and grows on the contractile fibers behind the cells. Because migrasomes contain various small vesicles shaped like pomegranates, they are also called pomegranate-like structures. They are rich in specific four-transmembrane proteins (membrane proteins), such as TSPAN4, which are involved in regulating the formation of migrasomes. Studies have found that migrasomes are rich in mRNA and proteins that are released into the extracellular matrix or transferred laterally to recipient cells to mediate intercellular communication and material transfer. At present, scholars at home and abroad have made initial progress in the functional research of migrasomes, but their mechanism of action in BCBM is still unclear.
[0004] Studies have shown that migrasomes exist in urine and can be used as a biomarker for early diagnosis of renal injury. Migrasomes have also been found in human serum, indicating that migrasomes may transmit signal molecules over long distances through blood circulation, thereby regulating the morphological changes of various organs in the body. The research team previously found that BCBM cell-derived migrasomes activate the PI3K-Akt signaling pathway by releasing the content-integrin β3 (ITGβ3) to induce the activation of M2 microglia, and the activated M2 microglia further promote brain metastasis of breast cancer by secreting transforming growth factor β1 (TGFβ1). This shows that ITGβ3 plays an important role in BCBM, but the content of serum migrasomes in BCBM patients, breast cancer patients and normal people is still unclear. Due to the low content of serum migrasomes, it is difficult to monitor by ordinary PCR technology, so we seek a new diagnostic technology to detect the expression of ITGβ3 in serum migrasomes.
[0005] Digital PCR (dPCR) is a new technology developed based on microfluidics. It converts samples into multiple independent nanoscale droplets and determines the absolute quantification of the target protein based on Poisson distribution. This method has high sensitivity and a detection limit of 0.01% or even lower, which is conducive to the detection of samples with low nucleic acid content. It can absolutely quantify serum migratoria ITGβ3 without making a standard curve. dPCR technology also has high accuracy and repeatability.
[0006] Studies have found that dPCR provides a powerful tool for liquid biopsy diagnosis and monitoring of breast cancer, liver cancer, and leukemia. Studies have shown that dPCR has a cancer detection rate that is about 2 times higher than qPCR (Real-time Quantitative PCR Detecting System, qPCR). dPCR testing can clearly distinguish between benign and malignant tumors (which can reduce the number of puncture biopsies), while qPCR testing can only detect malignant tumors. Therefore, dPCR technology provides important application value for early diagnosis and monitoring of clinical tumors and subsequent prognosis and treatment. Summary of the invention
[0007] In view of the problems existing in the prior art, the present invention provides a detection kit for serum migratoria marker ITGβ3 and its application as a molecular marker for breast cancer brain metastasis, which fills the current shortcoming of lack of BCBM-related detection.
[0008] The present invention is achieved through the following technical solutions: A detection kit for serum migratoria marker ITGβ3, comprising an upstream primer and a downstream primer; The nucleotide sequence of the upstream primer is shown in SEQ ID NO:1, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO:2.
[0009] The present invention also discloses the application of the serum migratoria marker ITGβ3 as a molecular marker for brain metastasis of breast cancer.
[0010] Furthermore, the serum migratoria marker ITGβ3 was detected by dPCR method, comprising the following steps: (1) RNA extraction, processing and reverse transcription: serum migratoria were extracted from blood, total migratoria RNA was extracted using TRIzol, and reverse transcribed to obtain cDNA; (2) dPCR amplification: Establish a dPCR amplification system, perform amplification reaction, and collect fluorescence signals; Furthermore, in step (2), the dPCR amplification system includes 7 μL cDNA, 11 μL 2×dPCR EvaGreen Master Mix, 1.0 μL upstream primer, 1.0 μL downstream primer, and ddH2O is used to adjust the total volume to 22 μL.
[0011] Furthermore, the reaction procedure of the amplification reaction in step (2) is as follows: droplet spreading at 60 °C for 5 min; Taq enzyme hot start at 95 °C for 15 min, each for 1 cycle; 95 °C for 15 s, 60 °C for 30 s, for 40 cycles; fluorescence signal collection at 60 °C for 60 s, for 1 cycle.
[0012] Furthermore, the concentration of the upstream primer and the downstream primer is 10 μM.
[0013] The present invention found that ITGβ3 in serum migrasomes can be used as a molecular marker of BCBM, showing significant application potential and important value in the clinical diagnosis of patients with breast cancer brain metastasis (BCBM). It can not only predict the presence of BCBM early, provide key information for the accurate diagnosis of patients, but also provide a reference for evaluating the prognosis of breast cancer. The migrasomes in the present invention are extracellular vesicles with a size of 500-3000nm. As the migration movement occurs, the tail or intersection of the cell contractile filaments generates a vesicle structure. Serum migrasome ITGβ3 is highly expressed in BCBM patients and lowly expressed in other breast cancer patients and normal people; ITGβ3 is highly expressed in cancer tissues of BCBM patients and lowly expressed in breast cancer and normal tissues. When ITGβ3 in BCBM cells (231-BR) is knocked out by lentivirus, BCBM cell proliferation, migration and invasion can be inhibited.
[0014] Beneficial Effects The present invention uses serum migratoria ITGβ3 as a BCBM molecular marker, designs upstream primers and downstream primers for detecting serum migratoria ITGβ3, and detects the differential expression of mRNA in serum migratoria ITGβ3 of patients by dPCR method, which has the advantages of high sensitivity, strong specificity, high accuracy and absolute quantification, and shows significant application potential and important value in the clinical diagnosis of BCBM patients. It can not only predict the presence of BCBM early, provide key information for accurate diagnosis of patients, but also provide a reference for evaluating the prognosis of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The results of differentially expressed proteins in Mig-BC and Mig-BCBM are shown in Figure 1. A is an overlap map, B is a heat map, and C is a volcano map. Figure 2 Figure 1 is a transmission electron micrograph of serum migrasomes and the expression of protein markers. A is a transmission electron micrograph of serum migrasomes, and B is a graph showing the expression of protein markers PIGK, NDST1, and TSPAN4 in serum migrasomes. Figure 3 The effects of lentiviral knockout of ITGβ3 in 231-BR on the proliferation, migration and invasion of breast cancer metastatic cells. A. Fluorescence microscopy of ITGβ3 knockout efficiency in 231-BR cells; B. qPCR detection of ITGβ3 knockout efficiency in 231-BR cells; C. Western Blot experiment of ITGβ3 knockout in 231-BR cells; D. Cell proliferation after ITGβ3 knockout in 231-BR cells; E. Cell migration and invasion after ITGβ3 knockout in 231-BR cells; F. Monoclonal experiment of ITGβ3 knockout in 231-BR cells; Figure 4 The figure shows the expression of ITGβ3 in cancer tissues of patients with breast cancer and BCBM; Figure 5 The content changes of ITGβ3 in serum of BCBM patients, breast cancer patients and normal people were analyzed. DETAILED DESCRIPTION
[0016] The present invention is described in detail below in conjunction with specific embodiments, but the protection scope of the present invention is not limited by the embodiments. All technologies implemented based on the above content of the present invention are included in the scope of protection intended by the present invention.
[0017] Main experimental materials: 1. Serum: 10 serum samples were collected from BCBM patients, breast cancer patients and normal people from January 2016 to March 2024. In addition, normal breast tissue, breast cancer adjacent tissue and cancerous tissue were collected from 10 breast cancer patients and BCBM patients; 2. Primers: All primers in this invention were synthesized by Sangon Biotech (Shanghai) Co., Ltd.; 3. Antibodies: The PIGK antibodies used in the present invention were purchased from Abcam, USA; NDST1 was purchased from Sigma, USA; TSPAN4 was purchased from Thermo Fisher, USA; and ITGβ3 was purchased from Cell Signaling Technology, USA.
[0018] Main reagents: 1. Migrate body purification kit: purchased from Sigma, USA; 2. RNA extraction, reverse transcription and dPCR reagents: RNA extraction TRIzol was purchased from ThermoFisher, reverse transcription reagent was purchased from Beijing Bio-Tech, and 2×dPCR EvaGreen Master Mix was purchased from Suzhou Sinafo Medical Technology Co., Ltd. 3. Western-blot reagents: Cell lysis buffer RIPA, 30% acrylamide, protein BCA quantitative reagent, PVDF membrane, skimmed milk powder were purchased from Beijing Biyuntian Company, ECL developer was purchased from Thermo Fisher Scientific, PageRuler TM Prestained Protein Ladder was purchased from Thermo Scientific, USA; 4. ITGβ3 RNAi-customized-lentiviral particles were purchased from Shanghai Gene Gene Technology Co., Ltd., and puromycin was purchased from Beijing Bio-Tech Company; 5. Immunohistochemistry reagents: cleaning solution, dewaxing solution, probe cleaning system, open reagent bottles, printed label paper and ribbon, Bond universal slide cover tile (cover plate), titration reagent bottle, mixing station and antigen retrieval solution were all purchased from Leica Biosystems, Germany.
[0019] Main reagent formula: 1. 50×TBS formula: Dissolve Tris-base in 800mL double distilled water, adjust pH=7.5 with concentrated HCL, dilute to 1000mL with double distilled water, and store at room temperature; 2. 10% ammonium persulfate: 0.1 g ammonium persulfate dissolved in 1 mL double distilled water; 3. 5% skim milk powder: 2.5 g skim milk powder dissolved in 50 mL TBST; 4. Preparation of electron microscope fluid: 0.2M electron microscope fixative with PBS buffer (10mL system, pH=7.2); NaH2PO4·2H2O 0.87g + NaH2PO4·12H2O 5.16g + distilled water to make up to 100mL; 2.5% glutaraldehyde (100mL system): 0.2M PBS (pH=7.2) 50mL + 25% glutaraldehyde 10mL + distilled water to make up to 100mL, store at 4℃.
[0020] Example 1 Proteomics detection of differential expression of cell migrasome contents Density gradient centrifugation was used to purify the cell migration bodies. The specific steps are as follows: (1) Extraction and purification of cell migratory bodies: Collect breast cancer parental cells (MDA-MB-231) and BCBM cells (231-BR), discard the culture medium, wash the cells with PBS, and discard the PBS; digest with trypsin, add culture medium to terminate the trypsin reaction, transfer the cells to a 50 ml centrifuge tube by pipetting; centrifuge at 4°C, 1000g for 10 min, retain the supernatant, centrifuge at 4°C, 4000g for 20 min, remove the cell pellet, and retain the supernatant; centrifuge at 4°C, 20,000g for 30-40 min, and retain the pellet, which is the crude extracted migratory body. Then, density gradient centrifugation was used to purify the migratoria: the crude migratoria was resuspended in 400ul of extraction buffer, and the migratoria was separated and purified by density gradient centrifugation using Optiprep as the density medium (Sigma-Aldrich, LYSISO1); first, a step gradient was established, starting from 27% (800µl), followed by 22.5% (1000µl), crude migratoria (19%, 1585µl), 16% (1000µl), 12% (900µl), and 8% (300µl). The pellet was first resuspended in 650 µl of dilution buffer, and then mixed with 400 µl of 1× extraction buffer, 30 µl of 2.3M sucrose, and 505 µl of 60% Optiprep to prepare a crude sample. Secondly, the prepared gradient solution was centrifuged at 150 000×g for 4 h at 4°C. Samples were collected from top to bottom (500-700µl for each fraction). Each component was mixed with an equal amount of PBS and centrifuged at 20000 g for 30 min to collect the precipitate, which was the purified migrator Mig-BC and Mig-BCBM.
[0021] (2) In order to obtain the differentially expressed proteins in Mig-BC and Mig-BCBM, 4D-Label-free quantitative proteomics technology was used to conduct research. The results of differentially expressed proteins in Mig-BC and Mig-BCBM are as follows: Figure 1As shown in the figure, the Venn diagram was used to analyze the overlap of identification between Mig-BCBM and Mig-BC, and the hierarchical clustering algorithm was used to group and classify the differentially expressed proteins in the comparison group, and the heat map was used to display the significant differences in proteins between the two groups. The volcano map was used to compare the significant differences in proteins between the two groups, in which the significantly down-regulated proteins were marked in blue, the significantly up-regulated proteins were marked in red, and the proteins with no difference were gray. A is the overlap of proteins expressed in Mig-BC and Mig-BCBM, with a total of 1458 overlapping proteins; B is the heat map of differentially expressed proteins in Mig-BC and Mig-BCBM, showing that the differences in proteins within the group are not large, and the differences in protein data between the groups are significant. C is the volcano map of differentially expressed proteins in Mig-BC and Mig-BCBM, showing the expression of differential proteins between the two groups, including ITGβ3 protein.
[0022] Example 2 Extraction and identification of serum migratory bodies (1) Extraction and purification of serum migratoria: Blood samples from normal people, breast cancer patients and BCBM patients were collected in a coagulation vacuum tube using a standard venipuncture protocol; serum was extracted by centrifugation at 3000 rpm for 10 min; 5 ml of cell-free serum was required for one purification. Centrifuge at 1000 g for 10 minutes and 4000 g for 20 minutes to remove large debris and keep the supernatant; centrifuge at 20000 g for 30 minutes to collect the coarse particles and wash with PBS; collect the precipitate with 400 µl of Extration buffer and purify the migratoria by density gradient centrifugation using Optiprep as the density medium (Sigma-Aldrich, LYSISO1). First, a step gradient was established, starting from 27% (800µl), followed by 22.5% (1000µl), 19% (1000µl), 16% (1000µl), 12% (900µl), 8% (300µl), crude Optiprep fraction (4% Diluted Optiprep Fraction), centrifuged at 150 000×g for 4 h at 4°C. Samples were collected from top to bottom (500-700µl for each fraction). Each fraction was mixed with an equal amount of PBS and centrifuged at 20000g for 30 min to collect the precipitate, which was the purified serum Optiprep fraction.
[0023] (2) Transmission electron microscopy (TEM): The migrator was resuspended in 20 μl PBS, gently blown, and an equal amount of electron microscopy fixative was added. The mixture was fixed at room temperature in the dark for 2 h and placed in a 4°C refrigerator for later use. The copper mesh with the support film was placed in contact with the surface of the sample solution and allowed to stand for 5 min. The copper mesh was removed and the excess suspension on the copper mesh was absorbed with filter paper. The copper mesh was transferred to sterile distilled water for washing and the excess water was absorbed with filter paper. The copper mesh was transferred to 1% uranyl acetate stain and stained for 2 min. The remaining dye on the copper mesh was absorbed with filter paper and then washed with distilled water. The excess water was absorbed with filter paper. The copper mesh was dried and put on the machine for observation.
[0024] (3) Western-blot: Migration-related proteins were extracted using RIPA reagent (Beyotime, Beijing, China). Protein concentration was determined using a BCA protein assay kit (Beyotime, Beijing, China); proteins were separated by 10–15% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane; the membrane was then blocked with 5% milk and incubated with primary antibodies against PIGK (1:1000, #ab201693, Abcam, USA), TSPAN4 (1:1000, #PA5-69344, Thermo Fisher, USA), and NDST1 (1:1000, #SAB1307040, Sigma, MO, USA) at 4°C overnight; after washing the membrane with TBST, it was incubated with enzyme-labeled secondary antibodies (HRP-labeled goat anti-rabbit IgG (H+L), #A0208, Beyotime; HRP-labeled goat anti-mouse IgG (H+L), #A0216, Beyotime) at room temperature for 1 h, followed by enhanced chemiluminescence reagent (Thermo Fisher Scientific, Waltham, MA, USA). incubated and visualized by a chemiluminescence imaging system (Tanon, Shanghai, China).
[0025] Transmission electron microscopy and protein marker expression of serum migratory bodies are shown in the figure below. Figure 2 As shown, the transmission electron microscopy (TEM) image of the serum migrator is as follows Figure 2 As shown in Figure A, transmission electron microscopy results confirmed that the size of the migratoria was about 500-3000 nm, indicating that the serum migratoria had been successfully purified. The expression of protein markers PIGK, NDST1, and TSPAN4 in the serum migratoria was shown in Figure 2. Figure 2 As shown in B, PIGK, NDST1, and TSPAN4 are markers of migratory body proteins. Western Blot experiments showed that PIGK, NDST1, and TSPAN4 were detected in the serum migratory bodies of normal people, breast cancer patients, and BCBM patients.
[0026] Example 3 Lentiviral knockout of ITGβ3 in BCBM cells (231-BR) inhibits BCBM cell proliferation, migration and invasion In this example, lentiviral infection was first used to construct a 231-BR cell line with stable ITGβ3 knockout, and CCK-8, monoclonal cloning, and Transwell chamber were used to detect the malignant cell morphology of 231-BR cells. The specific steps are as follows: (1) After the cells have grown to the logarithmic phase, 5×10 4 Cell suspension with a density of 1 cell / ml was inoculated into a six-well plate, with 2 ml of cell suspension in each well, and the plate was placed in a 5% CO2, 37°C incubator for incubation; lentiviral infection: when the cell density grew to a confluence of 60-70%, the plate was replaced with 1 ml of fresh culture medium without fetal bovine serum containing 40 μl Hitrans GP and an appropriate amount of sh-ITGβ3 lentiviral suspension (Gene Gene, Shanghai) and placed in an incubator for incubation; after 16 h of incubation, the plate was replaced with normal fresh culture medium and further cultured; 72 h after cell infection, the plate was immediately replaced with fresh culture medium containing 1 μg / ml puromycin, and after 48 h of incubation, 231-BR cells with stable ITGβ3 knockout were selected; the cell transfection efficiency was observed under a fluorescence microscope, and the success of ITGβ3 knockout was further detected by qRT-PCR and Western-blot experiments.
[0027] (2) CCK-8 experiment: After the cells grew to the logarithmic phase, 3×10 3 Cells / 200 μl of cell suspension were inoculated into 96-well plates. 231-BR (sh-NC or sh-ITGβ3) was used at 3×10 3 The cells were inoculated in 96-well plates, with 3 replicates in each group. At specific time points (0, 24, and 48 h), 10 μl of CCK-8 solution was added to each well and the cells were incubated in a cell culture incubator for 3 h. The absorbance at 450 nm was measured with an enzyme reader; the cell proliferation curve was drawn based on the OD value.
[0028] (3) Cell monoclonal experiment: After the cells grew to the logarithmic phase, 8×10 2 The cell suspension with a density of 10 cells / ml was inoculated into a six-well plate. After the cells grew to 15 days, they were fixed with 4% paraformaldehyde, stained with crystal violet, and observed under an inverted fluorescence microscope, and 6 fields of view were randomly photographed in each well.
[0029] (4) Cell migration assay: Before the experiment, 70 μl serum-free culture medium was used to hydrate the upper chamber of the Transwell plate for half an hour, and then the culture medium was aspirated and discarded. 100 μl cell suspension (1×104 / well), add 800μl of complete medium containing 10% serum to the lower chamber, put the upper chamber into the lower chamber to avoid bubbles, and place the Transwell plate in the cell culture incubator for 24h, then take out the upper chamber of Transwell and fix it with 4% paraformaldehyde. Stain with crystal violet, observe under an inverted fluorescence microscope and randomly take 6 fields of view for each well.
[0030] (5) Cell invasion assay: Thaw the ECM gel in an ice-water mixture, prepare a diluent at a ratio of ECM gel: serum-free culture medium = 1:9, use a pre-cooled pipette tip to draw 40 μl of the ECM dilution and evenly add it to the upper chamber of the Transwell plate, avoiding bubbles, and place the chamber in a cell culture incubator to solidify for 4 h; add 100 μl of cell suspension (1×10 4 / well) were added to the upper chamber of the Transwell plate, and 800μl of complete culture medium was added to the lower chamber. After the cells were cultured for 24h, the upper chamber of the Transwell was taken out and fixed with 4% paraformaldehyde; the cells were stained with crystal violet, observed under an inverted fluorescence microscope, and 6 fields of view were randomly photographed in each well.
[0031] Effects of lentiviral knockout of ITGβ3 in 231-BR on proliferation, migration and invasion of breast cancer metastatic cells Figure 3 As shown, A. Fluorescence microscopy of ITGβ3 knockout efficiency in 231-BR cells; B. qPCR detection of ITGβ3 knockout efficiency in 231-BR cells; C. Western Blot experiment of ITGβ3 knockout in 231-BR cells; D. Cell proliferation after ITGβ3 knockout in 231-BR cells; E. Cell migration after ITGβ3 knockout in 231-BR cells; F. Cell invasion after ITGβ3 knockout in 231-BR cells; G. Monoclonal experiment of ITGβ3 knockout in 231-BR cells. Figure 3 In Figure A, cells were infected with lentivirus (Lv-sh-ITGβ3) and the knockout efficiency of ITGβ3 in 231-BR cells was observed using a fluorescence microscope. Figure 3 In B, qPCR was used to further detect the knockout efficiency of ITGβ3, and it was found that ITGβ3 was knocked out by 60% in 231-BR cells. Figure 3 Figure C further demonstrates that the expression of ITGβ3 was successfully knocked out in 231-BR cells through lentiviral infection using Western Blot experiments. Figure 3 In Figure D, CCK-8 assay revealed that the cell proliferation rate in the knockout group (sh-ITGβ3) was decreased compared with that in the control group (sh-NC). Figure 3EF, cell migration, invasion and monoclonal experiments showed that after knocking out ITGβ3 in 231-BR cells, the number of cell migration and invasion decreased, and cell proliferation decreased. The above results indicate that knocking out ITGβ3 in 231-BR cells can inhibit the proliferation, migration and invasion of BCBM cells.
[0032] Example 4 ITGβ3 is highly expressed in cancer tissues of breast cancer and BCBM patients, but is lowly expressed in adjacent normal tissues In this example, Leica Bond Max fully automatic immunohistochemistry machine was used to detect the localization and expression of ITGβ3 in breast cancer and adjacent tissues. The specific steps are as follows: (1) Tissue dehydration, embedding and sectioning: Breast cancer (BC), BCBM patient cancer tissue and normal tissue (Normal) were cut into tissue blocks of appropriate size and fixed in 4% paraformaldehyde for 48 hours. After fixation, the tumor tissue and normal breast tissue were removed and washed with PBS. The tissue was dehydrated in a gradient manner: 70% ethanol soaked for 30 minutes-80% ethanol soaked for 30 minutes-90% ethanol soaked for 30 minutes-95% ethanol I soaked for 30 minutes-95% ethanol II soaked for 30 minutes to dehydrate-absolute ethanol I soaked for 30 minutes-absolute ethanol II soaked for 30 minutes-xylene I soaked for 1 hour-xylene II soaked for 2 hours. Then use an embedding machine to embed the tissue. Trim the wax block and perform tissue sectioning.
[0033] (2) Fully automated immunohistochemistry experiment: Place tissue sections in a 60°C incubator for 2 h for dewaxing. After dewaxing, perform immunohistochemistry experiments according to the instructions of the Leica Bond Max fully automated immunohistochemistry machine.
[0034] The expression of ITGβ3 in cancer tissues of breast cancer and BCBM patients is shown in the figure Figure 4 As shown, the results showed that ITGβ3 was mainly localized on the cell membrane of breast cancer cells, and the expression of ITGβ3 in BCBM tissues was increased compared with normal tissues and breast cancer tissues.
[0035] Example 5 A kit for detecting brain metastasis of breast cancer, comprising an upstream primer and a downstream primer; The nucleotide sequence of the upstream primer is shown in SEQ ID NO: 1, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO: 2; SEQ ID NO:1 5'-ATTCCCATGAGTTGGCTGGG-3' SEQ ID NO:2 5'-GCACTGTGGCCTCTCAGATT-3' The above kit was used to detect the changes in the mRNA expression of ITGβ3 in serum migratory bodies using dPCR technology: (1) RNA extraction, processing and reverse transcription: Serum migrasomes were extracted from normal subjects, breast cancer patients and BCBM patients, and total RNA of migrasomes was extracted using TRIzol. Reverse transcription was performed according to the instructions of the reverse transcription kit.
[0036] (2) dPCR amplification: amplification system: 7 μL cDNA, 11 μL 2×dPCR EvaGreen Master Mix, 1.0 μL upstream primer (10 μM), 1.0 μL downstream primer (10 μM), and ddH2O to adjust the total volume to 22 μL; amplification conditions: droplet spreading at 60°C for 5 min, Taq enzyme hot start at 95°C for 15 min, each for 1 cycle; 95°C for 15 s, 60°C for 30 s, for 40 cycles; fluorescence signal acquisition at 60°C for 60 s, for 1 cycle.
[0037] The changes of ITGβ3 content in serum migration of BCBM patients, breast cancer patients and normal people are shown in the figure Figure 5 The results showed that compared with the normal population and breast cancer patients' serum migrasomes, the expression of ITGβ3 in BCBM patients' serum migrasomes was higher, and the difference was statistically significant ( p <0.05). This indicates that ITGβ3 is highly expressed in the serum of BCBM patients, suggesting that serum migratoria ITGβ3 can be used as a molecular marker for BCBM and a target for the development of new BCBM drugs.
Claims
1. A detection kit for serum migratoria marker ITGβ3, characterized in that: Includes upstream primers and downstream primers; The nucleotide sequence of the upstream primer is shown in SEQ ID NO:1, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO:
2.
2. Use of the serum migratoria marker ITGβ3 according to claim 1 as a molecular marker for brain metastasis of breast cancer.
3. The use according to claim 2, characterized in that: The dPCR method was used to detect the serum migratoria marker ITGβ3, including the following steps: (1) RNA extraction, processing and reverse transcription: Serum migratoria were extracted from blood, total migratoria RNA was extracted using TRIzol, and reverse transcribed to obtain cDNA; (2) dPCR amplification: Establish a dPCR amplification system, perform amplification reactions, and collect fluorescence signals.
4. The use according to claim 3, characterized in that In step (2), the dPCR amplification system includes 7 μL cDNA, 11 μL 2×dPCR EvaGreen Master Mix, 1.0 μL upstream primer, 1.0 μL downstream primer, and ddH2O to adjust the total volume to 22 μL.
5. The use according to claim 3, characterized in that: The reaction procedure of the amplification reaction in step (2) is as follows: droplet spreading at 60 °C for 5 min; Taq enzyme hot start at 95 °C for 15 min, 1 cycle each; 95 °C for 15 s, 60 °C for 30 s, 40 cycles; fluorescence signal acquisition at 60 °C for 60 s, 1 cycle.
6. The use according to claim 4, characterized in that: The concentration of the upstream primer and the downstream primer is 10 μM.
Citation Information
Patent Citations
Transfer marker
CN115951057A
Application of serum transporter ATF6 as breast cancer brain metastasis molecular marker
CN117737240A
Breast cancer marker integrin beta3 and application thereof in breast cancer treatment
CN117867119A
Drug for inhibiting tumor cell metastasis and use thereof
WO2023016509A1
Cited By
Serum transporter identification method
CN120948798A
